Medical News

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

5. 12. 2023 Source: Diabetes

Modern antidiabetics –⁠ gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) –⁠ significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio -⁠ and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been shown…

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i, i.e., gliflozins) regardless of glycemic compensation in patients with type 2 diabetes (T2DM) and kidney…

5. 12. 2023 Source: Diabetes

Doc. Miloslav Salavec: We Still Encounter Delayed Initiation of Biological Treatment in AD and Many Other Diagnoses

Not all patients with atopic dermatitis (AD) who are indicated for biological treatment with dupilumab manage to reach centers where the treatment is provided. It's even more unfortunate when there's…

4. 12. 2023 Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation

Dual Inhibition of IL-17A/IL-17F Across the Spectrum of Axial Spondyloarthritis

Many patients with axial spondyloarthritis (axSpA) still have a need to seek additional therapeutic options and new mechanisms of action for medicinal substances. Phase III studies BE MOBILE 1 and 2…

1. 12. 2023 Source: Rheumatic Diseases

Effectiveness and Safety of Initiating Treatment for Primary Immunodeficiency with Subcutaneously Administered Immunoglobulins –⁠ A Systematic Review of the Literature

The aim of the systematic review of the literature published last year was to evaluate the effectiveness and safety of initiating treatment with subcutaneously administered immunoglobulins (SCIG) in…

1. 12. 2023 Source: Primary and Secondary Immunodeficiencies

10 Warning Signs of Primary and Secondary Immunodeficiencies

The Jeffrey Modell Foundation (JMF) proposed 10 warning signs of primary immunodeficiencies (PID). The study presented below examined whether they are applicable to secondary immunodeficiencies (SID)…

1. 12. 2023 Source: Primary and Secondary Immunodeficiencies

Picking from the Red Book of the CHS: What's New in This Year's Recommendations for Diagnosis and Treatment of AML?

In recent years, there have been significant advances in the diagnosis and therapy of acute myeloid leukemia (AML). High-quality laboratory diagnostics (molecular genetics, cytogenetics, and flow…

29. 11. 2023 Source: Acute Myeloid Leukemia

Educational Brochure for Patients with CLL

Thanks to the expansion of modern therapies for chronic lymphocytic leukemia, many patients now have regimens based on venetoclax. Do you want to help them better understand the practical aspects and...

28. 11. 2023 Source: Chronic Lymphocytic Leukemia

Bacterial Biofilm as a Complication of Respiratory Disease Treatment

One of the unique characteristics of certain microorganisms is their ability to form organized communities enveloped in extracellular polymeric matrix and firmly attached to a solid surface or…

28. 11. 2023 Source: Cough Therapy

Impact of erdostein on bacterial biofilm −⁠ and what it means for clinical practice?

One of the substances that could potentially influence the success of treatments for infections associated with biofilm formation in the future is erdostein. This medication is used in the treatment…

28. 11. 2023 Source: Cough Therapy

Low Molecular Weight Heparin in an ECMO Patient −⁠ Case Study

Extracorporeal membrane oxygenation (ECMO) has an irreplaceable role in intensive care medicine. In the context of preventing complications caused by blood clot formation, unfractionated heparin is…

28. 11. 2023 Source: Thromboprophylaxis

Use of Enoxaparin in Patients After Implantation of Left Ventricular Assist Device

Left ventricular assist devices (LVAD) are utilized in patients with end-stage heart failure (HF). Warfarin is typically employed for long-term anticoagulation, but there are no standardized…

28. 11. 2023 Source: Thromboprophylaxis

Prophylaxis with Enoxaparin After Total Knee or Hip Replacement

Venous thromboembolic disease is a significant cause of complications in surgical patients during and after hospitalization. The authors of a recently published Portuguese observational study…

28. 11. 2023 Source: Thromboprophylaxis

What Are the Impacts of Not Administering Extended VTE Prophylaxis in Oncology Patients After GIT Surgeries?

In a freshly published retrospective study, experts from the University of Arkansas investigated how well the professional recommendation that cancer patients undergo extended venous thromboembolism…

28. 11. 2023 Source: Thromboprophylaxis

FEIBA in Real Clinical Practice –⁠ Fresh Data from the Observational Study FEIBA GO

FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and…

27. 11. 2023 Source: Hemophilia

1 … 17 18 19 20 21 … 111

Back Filter by speciality

Remove filters

Popular this week